View ValuationCathay Biotech 将来の成長Future 基準チェック /16Cathay Biotech利益と収益がそれぞれ年間17%と10.7%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に5.1% 16.8%なると予測されています。主要情報17.0%収益成長率16.81%EPS成長率Chemicals 収益成長30.6%収益成長率10.7%将来の株主資本利益率5.15%アナリストカバレッジLow最終更新日19 May 2026今後の成長に関する最新情報Price Target Changed • May 19Price target decreased by 8.6% to CN¥62.54Down from CN¥68.44, the current price target is provided by 1 analyst. New target price is 41% above last closing price of CN¥44.32. Stock is down 6.7% over the past year. The company is forecast to post earnings per share of CN¥1.18 for next year compared to CN¥0.82 last year.Major Estimate Revision • Aug 23Consensus EPS estimates increase by 28%, revenue downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from CN¥3.63b to CN¥3.46b. EPS estimate rose from CN¥0.71 to CN¥0.91. Net income forecast to grow 33% next year vs 48% growth forecast for Chemicals industry in China. Consensus price target down from CN¥63.00 to CN¥61.00. Share price rose 4.5% to CN¥51.28 over the past week.Price Target Changed • Aug 12Price target increased by 8.3% to CN¥67.18Up from CN¥62.00, the current price target is an average from 2 analysts. New target price is 9.6% above last closing price of CN¥61.30. Stock is down 23% over the past year. The company is forecast to post earnings per share of CN¥0.94 for next year compared to CN¥0.95 last year.Price Target Changed • Aug 15Price target increased to CN¥91.82Up from CN¥78.69, the current price target is provided by 1 analyst. New target price is 15% above last closing price of CN¥79.70. Stock is down 15% over the past year. The company is forecast to post earnings per share of CN¥1.31 for next year compared to CN¥1.04 last year.すべての更新を表示Recent updatesPrice Target Changed • May 19Price target decreased by 8.6% to CN¥62.54Down from CN¥68.44, the current price target is provided by 1 analyst. New target price is 41% above last closing price of CN¥44.32. Stock is down 6.7% over the past year. The company is forecast to post earnings per share of CN¥1.18 for next year compared to CN¥0.82 last year.Reported Earnings • Apr 24Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: CN¥0.82. Revenue: CN¥3.30b (up 11% from FY 2024). Net income: CN¥560.7m (up 15% from FY 2024). Profit margin: 17% (in line with FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 9.9%. Revenue is forecast to grow 8.4% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China.お知らせ • Mar 30Cathay Biotech Inc. to Report Q1, 2026 Results on Apr 30, 2026Cathay Biotech Inc. announced that they will report Q1, 2026 results on Apr 30, 2026Reported Earnings • Mar 05Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: EPS: CN¥0.83. Revenue: CN¥3.30b (up 11% from FY 2024). Net income: CN¥565.7m (up 16% from FY 2024). Profit margin: 17% (in line with FY 2024). Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) missed analyst estimates by 8.8%. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China.お知らせ • Dec 26Cathay Biotech Inc. to Report Fiscal Year 2025 Results on Apr 24, 2026Cathay Biotech Inc. announced that they will report fiscal year 2025 results on Apr 24, 2026Reported Earnings • Nov 01Third quarter 2025 earnings released: EPS: CN¥0.20 (vs CN¥0.17 in 3Q 2024)Third quarter 2025 results: EPS: CN¥0.20 (up from CN¥0.17 in 3Q 2024). Revenue: CN¥874.3m (up 13% from 3Q 2024). Net income: CN¥142.0m (up 45% from 3Q 2024). Profit margin: 16% (up from 13% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.お知らせ • Sep 30Cathay Biotech Inc. to Report Q3, 2025 Results on Oct 31, 2025Cathay Biotech Inc. announced that they will report Q3, 2025 results on Oct 31, 2025Major Estimate Revision • Aug 23Consensus EPS estimates increase by 28%, revenue downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from CN¥3.63b to CN¥3.46b. EPS estimate rose from CN¥0.71 to CN¥0.91. Net income forecast to grow 33% next year vs 48% growth forecast for Chemicals industry in China. Consensus price target down from CN¥63.00 to CN¥61.00. Share price rose 4.5% to CN¥51.28 over the past week.Reported Earnings • Aug 18Second quarter 2025 earnings released: EPS: CN¥0.24 (vs CN¥0.24 in 2Q 2024)Second quarter 2025 results: EPS: CN¥0.24. Revenue: CN¥895.0m (up 18% from 2Q 2024). Net income: CN¥171.7m (up 21% from 2Q 2024). Profit margin: 19% (in line with 2Q 2024). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Chemicals industry in China.Declared Dividend • Jul 30Dividend increased to CN¥0.40Dividend of CN¥0.40 is 111% higher than last year. Ex-date: 1st August 2025 Payment date: 1st August 2025 Dividend yield will be 0.8%, which is lower than the industry average of 2.6%. Sustainability & Growth Dividend is covered by earnings (45% earnings payout ratio) but not covered by cash flows (dividend approximately 8x free cash flows). The dividend has decreased over the past 46 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 37% over the next 3 years, which should provide support to the dividend and adequate earnings cover.お知らせ • Jun 30Cathay Biotech Inc. to Report First Half, 2025 Results on Aug 16, 2025Cathay Biotech Inc. announced that they will report first half, 2025 results on Aug 16, 2025お知らせ • Jun 04Cathay Biotech Inc., Annual General Meeting, Jun 27, 2025Cathay Biotech Inc., Annual General Meeting, Jun 27, 2025, at 14:00 China Standard Time. Location: 9F, No. 11, Lane 396, Lvzhou Ring Road, Minhang District, Shanghai ChinaBoard Change • May 10Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 9 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Xiang Yang Wu was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.New Risk • Apr 25New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.8% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.5% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (24% increase in shares outstanding).Reported Earnings • Apr 23Full year 2024 earnings released: EPS: CN¥0.84 (vs CN¥0.63 in FY 2023)Full year 2024 results: EPS: CN¥0.84 (up from CN¥0.63 in FY 2023). Revenue: CN¥2.96b (up 40% from FY 2023). Net income: CN¥489.0m (up 33% from FY 2023). Profit margin: 17% (in line with FY 2023). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.お知らせ • Mar 28Cathay Biotech Inc. to Report Q1, 2025 Results on Apr 30, 2025Cathay Biotech Inc. announced that they will report Q1, 2025 results on Apr 30, 2025Reported Earnings • Feb 28Full year 2024 earnings released: EPS: CN¥0.84 (vs CN¥0.63 in FY 2023)Full year 2024 results: EPS: CN¥0.84 (up from CN¥0.63 in FY 2023). Revenue: CN¥2.96b (up 40% from FY 2023). Net income: CN¥486.7m (up 33% from FY 2023). Profit margin: 17% (in line with FY 2023). Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 20% per year.分析記事 • Feb 20Investors Could Be Concerned With Cathay Biotech's (SHSE:688065) Returns On CapitalWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...分析記事 • Jan 30Some Confidence Is Lacking In Cathay Biotech Inc.'s (SHSE:688065) P/EWith a price-to-earnings (or "P/E") ratio of 64.5x Cathay Biotech Inc. ( SHSE:688065 ) may be sending very bearish...分析記事 • Jan 09Does Cathay Biotech (SHSE:688065) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Dec 27Cathay Biotech Inc. to Report Fiscal Year 2024 Results on Apr 03, 2025Cathay Biotech Inc. announced that they will report fiscal year 2024 results on Apr 03, 2025分析記事 • Nov 07Cathay Biotech's (SHSE:688065) Profits Appear To Have Quality IssuesCathay Biotech Inc.'s ( SHSE:688065 ) robust recent earnings didn't do much to move the stock. We think this is due to...Reported Earnings • Oct 31Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.13 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.17 (up from CN¥0.13 in 3Q 2023). Revenue: CN¥770.8m (up 44% from 3Q 2023). Net income: CN¥97.7m (up 36% from 3Q 2023). Profit margin: 13% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 20% per year whereas the company’s share price has fallen by 24% per year.お知らせ • Oct 22Cathay Biotech Inc. (SHSE:688065) announces an Equity Buyback for CNY 20 million worth of its shares.Cathay Biotech Inc. announces a share repurchase program. Under the program, the company will repurchase up to CNY 20 million worth of its shares. The shares will be repurchased at a price of not more than CNY 67 per share. The repurchased shares will be used for employee stock ownership plans or equity incentives. Repurchases will be funded using company's own funds or self-raised funds. The program will be valid till 12 months from approval of board.分析記事 • Oct 22What Cathay Biotech Inc.'s (SHSE:688065) 38% Share Price Gain Is Not Telling YouCathay Biotech Inc. ( SHSE:688065 ) shareholders would be excited to see that the share price has had a great month...分析記事 • Oct 20Cathay Biotech (SHSE:688065) Could Be Struggling To Allocate CapitalIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to CN¥46.38, the stock trades at a trailing P/E ratio of 72.5x. Average trailing P/E is 31x in the Chemicals industry in China. Total loss to shareholders of 57% over the past three years.New Risk • Sep 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.4% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Large one-off items impacting financial results.お知らせ • Sep 30Cathay Biotech Inc. to Report Q3, 2024 Results on Oct 31, 2024Cathay Biotech Inc. announced that they will report Q3, 2024 results on Oct 31, 2024分析記事 • Sep 29Cathay Biotech (SHSE:688065) Seems To Use Debt Quite SensiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Valuation Update With 7 Day Price Move • Sep 27Investor sentiment improves as stock rises 23%After last week's 23% share price gain to CN¥40.70, the stock trades at a trailing P/E ratio of 63.6x. Average trailing P/E is 29x in the Chemicals industry in China. Total loss to shareholders of 63% over the past three years.分析記事 • Sep 07Cathay Biotech Inc.'s (SHSE:688065) Share Price Not Quite Adding UpWhen close to half the companies in China have price-to-earnings ratios (or "P/E's") below 27x, you may consider Cathay...New Risk • Aug 18New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 22% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.4% per year over the past 5 years. Minor Risk Large one-off items impacting financial results.Reported Earnings • Aug 16Second quarter 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.30 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.24 (down from CN¥0.30 in 2Q 2023). Revenue: CN¥759.8m (up 45% from 2Q 2023). Net income: CN¥142.2m (down 23% from 2Q 2023). Profit margin: 19% (down from 35% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.お知らせ • Jun 28Cathay Biotech Inc. to Report First Half, 2024 Results on Aug 31, 2024Cathay Biotech Inc. announced that they will report first half, 2024 results on Aug 31, 2024分析記事 • Jun 19There Are Reasons To Feel Uneasy About Cathay Biotech's (SHSE:688065) Returns On CapitalDid you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...お知らせ • Jun 06Cathay Biotech Inc., Annual General Meeting, Jun 27, 2024Cathay Biotech Inc., Annual General Meeting, Jun 27, 2024, at 14:00 China Standard Time. Location: 9F, No. 11, Lane 396, Lvzhou Ring Road, Minhang District, Shanghai China分析記事 • May 28Cathay Biotech (SHSE:688065) Has A Somewhat Strained Balance SheetThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • May 07What Cathay Biotech Inc.'s (SHSE:688065) 27% Share Price Gain Is Not Telling YouCathay Biotech Inc. ( SHSE:688065 ) shares have had a really impressive month, gaining 27% after a shaky period...分析記事 • May 06We Think That There Are More Issues For Cathay Biotech (SHSE:688065) Than Just Sluggish EarningsCathay Biotech Inc.'s ( SHSE:688065 ) stock showed strength, with investors undeterred by its weak earnings report. We...Reported Earnings • May 01Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: EPS: CN¥0.63 (down from CN¥0.95 in FY 2022). Revenue: CN¥2.11b (down 13% from FY 2022). Net income: CN¥366.5m (down 34% from FY 2022). Profit margin: 17% (down from 23% in FY 2022). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 33%. Earnings per share (EPS) also missed analyst estimates by 34%. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.Valuation Update With 7 Day Price Move • Apr 29Investor sentiment improves as stock rises 21%After last week's 21% share price gain to CN¥49.16, the stock trades at a trailing P/E ratio of 78.1x. Average trailing P/E is 32x in the Chemicals industry in China. Total loss to shareholders of 12% over the past three years.New Risk • Apr 09New major risk - Revenue and earnings growthEarnings have declined by 0.06% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.お知らせ • Mar 30Cathay Biotech Inc. to Report Q1, 2024 Results on Apr 30, 2024Cathay Biotech Inc. announced that they will report Q1, 2024 results on Apr 30, 2024Reported Earnings • Feb 24Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: EPS: CN¥0.63 (down from CN¥0.95 in FY 2022). Revenue: CN¥2.11b (down 13% from FY 2022). Net income: CN¥367.0m (down 34% from FY 2022). Profit margin: 17% (down from 23% in FY 2022). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 33%. Earnings per share (EPS) also missed analyst estimates by 34%. Revenue is forecast to grow 49% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 7% per year.お知らせ • Dec 29Cathay Biotech Inc. to Report Fiscal Year 2023 Results on Apr 30, 2024Cathay Biotech Inc. announced that they will report fiscal year 2023 results on Apr 30, 2024Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.25 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.13 (down from CN¥0.25 in 3Q 2022). Revenue: CN¥535.1m (down 2.5% from 3Q 2022). Net income: CN¥72.0m (down 52% from 3Q 2022). Profit margin: 14% (down from 27% in 3Q 2022). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 7% per year.お知らせ • Aug 18Cathay Biotech Inc. (SHSE:688065) announces an Equity Buyback for CNY 100 million worth of its shares.Cathay Biotech Inc. announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The program will be valid for a period of 12 months.Price Target Changed • Aug 12Price target increased by 8.3% to CN¥67.18Up from CN¥62.00, the current price target is an average from 2 analysts. New target price is 9.6% above last closing price of CN¥61.30. Stock is down 23% over the past year. The company is forecast to post earnings per share of CN¥0.94 for next year compared to CN¥0.95 last year.Reported Earnings • Aug 08Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.28 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.30 (up from CN¥0.28 in 2Q 2022). Revenue: CN¥525.0m (down 16% from 2Q 2022). Net income: CN¥184.4m (up 14% from 2Q 2022). Profit margin: 35% (up from 26% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.お知らせ • Jun 28Cathay Biotech Inc. to Report First Half, 2023 Results on Aug 16, 2023Cathay Biotech Inc. announced that they will report first half, 2023 results on Aug 16, 2023お知らせ • Jun 27Cathay Biotech Inc. announced that it expects to receive CNY 6.6 billion in funding from China Merchants Group LimitedCathay Biotech Inc. announced a private placement of common shares for gross proceeds up to CNY 6,600 million on June 25, 2023. The transaction will include participation from new investor China Merchants Group Limited. The transaction is subject to the approval of shareholders of the company.Reported Earnings • Apr 26Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: CN¥0.95 (down from CN¥1.04 in FY 2021). Revenue: CN¥2.44b (up 11% from FY 2021). Net income: CN¥553.3m (down 9.0% from FY 2021). Profit margin: 23% (down from 28% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 23%. Earnings per share (EPS) also missed analyst estimates by 23%.Reported Earnings • Mar 01Full year 2022 earnings released: EPS: CN¥0.95 (vs CN¥1.04 in FY 2021)Full year 2022 results: EPS: CN¥0.95 (down from CN¥1.04 in FY 2021). Revenue: CN¥2.44b (up 11% from FY 2021). Net income: CN¥552.4m (down 9.1% from FY 2021). Profit margin: 23% (down from 28% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 42% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Chemicals industry in China.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Nov 08Cathay Biotech Inc. announced that it has received $28 million in funding from Eight Roads Ventures, Sequoia China Investment Management LLP, Source Code Capital, Bits x BitesCathay Biotech Inc. announced that it has received $28,000,000 in a round of funding co-led by Eight Roads Ventures, Sequoia China Investment Management LLP on November 7, 2022. The transaction included participation from returning investors Source Code Capital, Bits x Bites.Reported Earnings • Oct 28Third quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.29 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.25 (down from CN¥0.29 in 3Q 2021). Revenue: CN¥548.9m (down 11% from 3Q 2021). Net income: CN¥149.7m (down 8.5% from 3Q 2021). Profit margin: 27% (in line with 3Q 2021). Revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.Price Target Changed • Aug 15Price target increased to CN¥91.82Up from CN¥78.69, the current price target is provided by 1 analyst. New target price is 15% above last closing price of CN¥79.70. Stock is down 15% over the past year. The company is forecast to post earnings per share of CN¥1.31 for next year compared to CN¥1.04 last year.Valuation Update With 7 Day Price Move • Jun 06Investor sentiment improved over the past weekAfter last week's 23% share price gain to CN¥106, the stock trades at a forward P/E ratio of 58x. Average forward P/E is 17x in the Chemicals industry in China. Total returns to shareholders of 11% over the past year.Valuation Update With 7 Day Price Move • May 03Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥91.69, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 14x in the Chemicals industry in China. Total returns to shareholders of 16% over the past year.Reported Earnings • Apr 27First quarter 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.34 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.42 (up from CN¥0.34 in 1Q 2021). Revenue: CN¥661.3m (up 36% from 1Q 2021). Net income: CN¥174.5m (up 24% from 1Q 2021). Profit margin: 26% (down from 29% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 20%, compared to a 43% growth forecast for the industry in China.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Apr 08Full year 2021 earnings released: EPS: CN¥1.46 (vs CN¥1.18 in FY 2020)Full year 2021 results: EPS: CN¥1.46 (up from CN¥1.18 in FY 2020). Revenue: CN¥2.20b (up 47% from FY 2020). Net income: CN¥607.9m (up 33% from FY 2020). Profit margin: 28% (down from 31% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 24%, compared to a 50% growth forecast for the industry in China.Valuation Update With 7 Day Price Move • Mar 08Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to CN¥115, the stock trades at a trailing P/E ratio of 79.6x. Average trailing P/E is 32x in the Chemicals industry in China. Total returns to shareholders of 43% over the past year.Reported Earnings • Feb 28Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: EPS: CN¥1.45 (up from CN¥1.18 in FY 2020). Revenue: CN¥2.20b (up 47% from FY 2020). Net income: CN¥603.6m (up 32% from FY 2020). Profit margin: 28% (down from 31% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 24%. Earnings per share (EPS) exceeded analyst estimates by 1.7%.Reported Earnings • Oct 31Third quarter 2021 earnings released: EPS CN¥0.40 (vs CN¥0.30 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: CN¥618.5m (up 72% from 3Q 2020). Net income: CN¥163.6m (up 42% from 3Q 2020). Profit margin: 26% (down from 32% in 3Q 2020). The decrease in margin was driven by higher expenses.Reported Earnings • Aug 19Second quarter 2021 earnings released: EPS CN¥0.44 (vs CN¥0.23 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥527.2m (up 36% from 2Q 2020). Net income: CN¥185.1m (up 110% from 2Q 2020). Profit margin: 35% (up from 23% in 2Q 2020). The increase in margin was driven by higher revenue.Reported Earnings • Apr 27First quarter 2021 earnings released: EPS CN¥0.34 (vs CN¥0.32 in 1Q 2020)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: CN¥487.0m (up 20% from 1Q 2020). Net income: CN¥141.3m (up 19% from 1Q 2020). Profit margin: 29% (in line with 1Q 2020).Reported Earnings • Apr 01Full year 2020 earnings released: EPS CN¥1.18 (vs CN¥1.32 in FY 2019)The company reported a soft full year result with weaker earnings and revenues, although profit margins were improved. Full year 2020 results: Revenue: CN¥1.50b (down 22% from FY 2019). Net income: CN¥457.7m (down 4.4% from FY 2019). Profit margin: 31% (up from 25% in FY 2019). The increase in margin was driven by lower expenses.お知らせ • Mar 05Cathay Biotech Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021Cathay Biotech Inc. announced that they will report fiscal year 2020 results on Mar 30, 2021Valuation Update With 7 Day Price Move • Feb 22Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥89.29, the stock is trading at a trailing P/E ratio of 78.6x, up from the previous P/E ratio of 67.7x. This compares to an average P/E of 37x in the Chemicals industry in China.Is New 90 Day High Low • Jan 27New 90-day low: CN¥82.67The company is down 10.0% from its price of CN¥92.00 on 29 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 21% over the same period.Is New 90 Day High Low • Dec 23New 90-day low: CN¥88.56The company is down 11% from its price of CN¥99.97 on 24 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 6.0% over the same period.業績と収益の成長予測SHSE:688065 - アナリストの将来予測と過去の財務データ ( )CNY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20284,5091,016N/A1,470112/31/20274,052943N/A744112/31/20263,568848N/A1,13613/31/20263,394589-463296N/A12/31/20253,295561-339404N/A9/30/20253,288594-327418N/A6/30/20253,18455088725N/A3/31/20253,04952133693N/A12/31/20242,958489-22821N/A9/30/20242,764398-157715N/A6/30/20242,528372-686681N/A3/31/20242,293414-840705N/A12/31/20232,114367-1,000569N/A9/30/20232,169381-1,515685N/A6/30/20232,183459-2,031766N/A3/31/20232,285436-2,889738N/A12/31/20222,441553-3,395804N/A9/30/20222,447605-3,399794N/A6/30/20222,517619-2,748601N/A3/31/20222,538628-1,848610N/A12/31/20212,363595-880579N/A9/30/20212,099612-409684N/A6/30/20211,839564-231637N/A3/31/20211,579481-48659N/A12/31/20201,497458-248515N/A9/30/20201,482428-139201N/A6/30/20201,601432-70403N/A3/31/20201,722475-337290N/A12/31/20191,916479N/A360N/A12/31/20181,757466N/A-10N/A12/31/20171,363333N/A53N/A12/31/2016929145N/A-129N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 688065の予測収益成長率 (年間17% ) は 貯蓄率 ( 2.4% ) を上回っています。収益対市場: 688065の収益 ( 17% ) CN市場 ( 27% ) よりも低い成長が予測されています。高成長収益: 688065の収益は増加すると予測されていますが、大幅には増加しません。収益対市場: 688065の収益 ( 10.7% ) CN市場 ( 16% ) よりも低い成長が予測されています。高い収益成長: 688065の収益 ( 10.7% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 688065の 自己資本利益率 は、3年後には低くなると予測されています ( 5.1 %)。成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 08:34終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cathay Biotech Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Junjun ZhuHaitong International Research LimitedTing Zhou ZhuangHuatai Research
Price Target Changed • May 19Price target decreased by 8.6% to CN¥62.54Down from CN¥68.44, the current price target is provided by 1 analyst. New target price is 41% above last closing price of CN¥44.32. Stock is down 6.7% over the past year. The company is forecast to post earnings per share of CN¥1.18 for next year compared to CN¥0.82 last year.
Major Estimate Revision • Aug 23Consensus EPS estimates increase by 28%, revenue downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from CN¥3.63b to CN¥3.46b. EPS estimate rose from CN¥0.71 to CN¥0.91. Net income forecast to grow 33% next year vs 48% growth forecast for Chemicals industry in China. Consensus price target down from CN¥63.00 to CN¥61.00. Share price rose 4.5% to CN¥51.28 over the past week.
Price Target Changed • Aug 12Price target increased by 8.3% to CN¥67.18Up from CN¥62.00, the current price target is an average from 2 analysts. New target price is 9.6% above last closing price of CN¥61.30. Stock is down 23% over the past year. The company is forecast to post earnings per share of CN¥0.94 for next year compared to CN¥0.95 last year.
Price Target Changed • Aug 15Price target increased to CN¥91.82Up from CN¥78.69, the current price target is provided by 1 analyst. New target price is 15% above last closing price of CN¥79.70. Stock is down 15% over the past year. The company is forecast to post earnings per share of CN¥1.31 for next year compared to CN¥1.04 last year.
Price Target Changed • May 19Price target decreased by 8.6% to CN¥62.54Down from CN¥68.44, the current price target is provided by 1 analyst. New target price is 41% above last closing price of CN¥44.32. Stock is down 6.7% over the past year. The company is forecast to post earnings per share of CN¥1.18 for next year compared to CN¥0.82 last year.
Reported Earnings • Apr 24Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: CN¥0.82. Revenue: CN¥3.30b (up 11% from FY 2024). Net income: CN¥560.7m (up 15% from FY 2024). Profit margin: 17% (in line with FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 9.9%. Revenue is forecast to grow 8.4% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China.
お知らせ • Mar 30Cathay Biotech Inc. to Report Q1, 2026 Results on Apr 30, 2026Cathay Biotech Inc. announced that they will report Q1, 2026 results on Apr 30, 2026
Reported Earnings • Mar 05Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: EPS: CN¥0.83. Revenue: CN¥3.30b (up 11% from FY 2024). Net income: CN¥565.7m (up 16% from FY 2024). Profit margin: 17% (in line with FY 2024). Revenue exceeded analyst estimates by 1.0%. Earnings per share (EPS) missed analyst estimates by 8.8%. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China.
お知らせ • Dec 26Cathay Biotech Inc. to Report Fiscal Year 2025 Results on Apr 24, 2026Cathay Biotech Inc. announced that they will report fiscal year 2025 results on Apr 24, 2026
Reported Earnings • Nov 01Third quarter 2025 earnings released: EPS: CN¥0.20 (vs CN¥0.17 in 3Q 2024)Third quarter 2025 results: EPS: CN¥0.20 (up from CN¥0.17 in 3Q 2024). Revenue: CN¥874.3m (up 13% from 3Q 2024). Net income: CN¥142.0m (up 45% from 3Q 2024). Profit margin: 16% (up from 13% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
お知らせ • Sep 30Cathay Biotech Inc. to Report Q3, 2025 Results on Oct 31, 2025Cathay Biotech Inc. announced that they will report Q3, 2025 results on Oct 31, 2025
Major Estimate Revision • Aug 23Consensus EPS estimates increase by 28%, revenue downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from CN¥3.63b to CN¥3.46b. EPS estimate rose from CN¥0.71 to CN¥0.91. Net income forecast to grow 33% next year vs 48% growth forecast for Chemicals industry in China. Consensus price target down from CN¥63.00 to CN¥61.00. Share price rose 4.5% to CN¥51.28 over the past week.
Reported Earnings • Aug 18Second quarter 2025 earnings released: EPS: CN¥0.24 (vs CN¥0.24 in 2Q 2024)Second quarter 2025 results: EPS: CN¥0.24. Revenue: CN¥895.0m (up 18% from 2Q 2024). Net income: CN¥171.7m (up 21% from 2Q 2024). Profit margin: 19% (in line with 2Q 2024). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Chemicals industry in China.
Declared Dividend • Jul 30Dividend increased to CN¥0.40Dividend of CN¥0.40 is 111% higher than last year. Ex-date: 1st August 2025 Payment date: 1st August 2025 Dividend yield will be 0.8%, which is lower than the industry average of 2.6%. Sustainability & Growth Dividend is covered by earnings (45% earnings payout ratio) but not covered by cash flows (dividend approximately 8x free cash flows). The dividend has decreased over the past 46 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 37% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
お知らせ • Jun 30Cathay Biotech Inc. to Report First Half, 2025 Results on Aug 16, 2025Cathay Biotech Inc. announced that they will report first half, 2025 results on Aug 16, 2025
お知らせ • Jun 04Cathay Biotech Inc., Annual General Meeting, Jun 27, 2025Cathay Biotech Inc., Annual General Meeting, Jun 27, 2025, at 14:00 China Standard Time. Location: 9F, No. 11, Lane 396, Lvzhou Ring Road, Minhang District, Shanghai China
Board Change • May 10Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 9 experienced directors. No highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Xiang Yang Wu was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
New Risk • Apr 25New minor risk - Dividend sustainabilityThe dividend is not well covered by cash flows. The company is paying a dividend despite having no free cash flows. Dividend yield: 0.8% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.5% per year over the past 5 years. Minor Risks Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (24% increase in shares outstanding).
Reported Earnings • Apr 23Full year 2024 earnings released: EPS: CN¥0.84 (vs CN¥0.63 in FY 2023)Full year 2024 results: EPS: CN¥0.84 (up from CN¥0.63 in FY 2023). Revenue: CN¥2.96b (up 40% from FY 2023). Net income: CN¥489.0m (up 33% from FY 2023). Profit margin: 17% (in line with FY 2023). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
お知らせ • Mar 28Cathay Biotech Inc. to Report Q1, 2025 Results on Apr 30, 2025Cathay Biotech Inc. announced that they will report Q1, 2025 results on Apr 30, 2025
Reported Earnings • Feb 28Full year 2024 earnings released: EPS: CN¥0.84 (vs CN¥0.63 in FY 2023)Full year 2024 results: EPS: CN¥0.84 (up from CN¥0.63 in FY 2023). Revenue: CN¥2.96b (up 40% from FY 2023). Net income: CN¥486.7m (up 33% from FY 2023). Profit margin: 17% (in line with FY 2023). Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 20% per year.
分析記事 • Feb 20Investors Could Be Concerned With Cathay Biotech's (SHSE:688065) Returns On CapitalWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...
分析記事 • Jan 30Some Confidence Is Lacking In Cathay Biotech Inc.'s (SHSE:688065) P/EWith a price-to-earnings (or "P/E") ratio of 64.5x Cathay Biotech Inc. ( SHSE:688065 ) may be sending very bearish...
分析記事 • Jan 09Does Cathay Biotech (SHSE:688065) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Dec 27Cathay Biotech Inc. to Report Fiscal Year 2024 Results on Apr 03, 2025Cathay Biotech Inc. announced that they will report fiscal year 2024 results on Apr 03, 2025
分析記事 • Nov 07Cathay Biotech's (SHSE:688065) Profits Appear To Have Quality IssuesCathay Biotech Inc.'s ( SHSE:688065 ) robust recent earnings didn't do much to move the stock. We think this is due to...
Reported Earnings • Oct 31Third quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.13 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.17 (up from CN¥0.13 in 3Q 2023). Revenue: CN¥770.8m (up 44% from 3Q 2023). Net income: CN¥97.7m (up 36% from 3Q 2023). Profit margin: 13% (in line with 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 20% per year whereas the company’s share price has fallen by 24% per year.
お知らせ • Oct 22Cathay Biotech Inc. (SHSE:688065) announces an Equity Buyback for CNY 20 million worth of its shares.Cathay Biotech Inc. announces a share repurchase program. Under the program, the company will repurchase up to CNY 20 million worth of its shares. The shares will be repurchased at a price of not more than CNY 67 per share. The repurchased shares will be used for employee stock ownership plans or equity incentives. Repurchases will be funded using company's own funds or self-raised funds. The program will be valid till 12 months from approval of board.
分析記事 • Oct 22What Cathay Biotech Inc.'s (SHSE:688065) 38% Share Price Gain Is Not Telling YouCathay Biotech Inc. ( SHSE:688065 ) shareholders would be excited to see that the share price has had a great month...
分析記事 • Oct 20Cathay Biotech (SHSE:688065) Could Be Struggling To Allocate CapitalIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to CN¥46.38, the stock trades at a trailing P/E ratio of 72.5x. Average trailing P/E is 31x in the Chemicals industry in China. Total loss to shareholders of 57% over the past three years.
New Risk • Sep 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.4% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Large one-off items impacting financial results.
お知らせ • Sep 30Cathay Biotech Inc. to Report Q3, 2024 Results on Oct 31, 2024Cathay Biotech Inc. announced that they will report Q3, 2024 results on Oct 31, 2024
分析記事 • Sep 29Cathay Biotech (SHSE:688065) Seems To Use Debt Quite SensiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Valuation Update With 7 Day Price Move • Sep 27Investor sentiment improves as stock rises 23%After last week's 23% share price gain to CN¥40.70, the stock trades at a trailing P/E ratio of 63.6x. Average trailing P/E is 29x in the Chemicals industry in China. Total loss to shareholders of 63% over the past three years.
分析記事 • Sep 07Cathay Biotech Inc.'s (SHSE:688065) Share Price Not Quite Adding UpWhen close to half the companies in China have price-to-earnings ratios (or "P/E's") below 27x, you may consider Cathay...
New Risk • Aug 18New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 22% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 3.4% per year over the past 5 years. Minor Risk Large one-off items impacting financial results.
Reported Earnings • Aug 16Second quarter 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.30 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.24 (down from CN¥0.30 in 2Q 2023). Revenue: CN¥759.8m (up 45% from 2Q 2023). Net income: CN¥142.2m (down 23% from 2Q 2023). Profit margin: 19% (down from 35% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.
お知らせ • Jun 28Cathay Biotech Inc. to Report First Half, 2024 Results on Aug 31, 2024Cathay Biotech Inc. announced that they will report first half, 2024 results on Aug 31, 2024
分析記事 • Jun 19There Are Reasons To Feel Uneasy About Cathay Biotech's (SHSE:688065) Returns On CapitalDid you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...
お知らせ • Jun 06Cathay Biotech Inc., Annual General Meeting, Jun 27, 2024Cathay Biotech Inc., Annual General Meeting, Jun 27, 2024, at 14:00 China Standard Time. Location: 9F, No. 11, Lane 396, Lvzhou Ring Road, Minhang District, Shanghai China
分析記事 • May 28Cathay Biotech (SHSE:688065) Has A Somewhat Strained Balance SheetThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • May 07What Cathay Biotech Inc.'s (SHSE:688065) 27% Share Price Gain Is Not Telling YouCathay Biotech Inc. ( SHSE:688065 ) shares have had a really impressive month, gaining 27% after a shaky period...
分析記事 • May 06We Think That There Are More Issues For Cathay Biotech (SHSE:688065) Than Just Sluggish EarningsCathay Biotech Inc.'s ( SHSE:688065 ) stock showed strength, with investors undeterred by its weak earnings report. We...
Reported Earnings • May 01Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: EPS: CN¥0.63 (down from CN¥0.95 in FY 2022). Revenue: CN¥2.11b (down 13% from FY 2022). Net income: CN¥366.5m (down 34% from FY 2022). Profit margin: 17% (down from 23% in FY 2022). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 33%. Earnings per share (EPS) also missed analyst estimates by 34%. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
Valuation Update With 7 Day Price Move • Apr 29Investor sentiment improves as stock rises 21%After last week's 21% share price gain to CN¥49.16, the stock trades at a trailing P/E ratio of 78.1x. Average trailing P/E is 32x in the Chemicals industry in China. Total loss to shareholders of 12% over the past three years.
New Risk • Apr 09New major risk - Revenue and earnings growthEarnings have declined by 0.06% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
お知らせ • Mar 30Cathay Biotech Inc. to Report Q1, 2024 Results on Apr 30, 2024Cathay Biotech Inc. announced that they will report Q1, 2024 results on Apr 30, 2024
Reported Earnings • Feb 24Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: EPS: CN¥0.63 (down from CN¥0.95 in FY 2022). Revenue: CN¥2.11b (down 13% from FY 2022). Net income: CN¥367.0m (down 34% from FY 2022). Profit margin: 17% (down from 23% in FY 2022). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 33%. Earnings per share (EPS) also missed analyst estimates by 34%. Revenue is forecast to grow 49% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 7% per year.
お知らせ • Dec 29Cathay Biotech Inc. to Report Fiscal Year 2023 Results on Apr 30, 2024Cathay Biotech Inc. announced that they will report fiscal year 2023 results on Apr 30, 2024
Reported Earnings • Nov 02Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.25 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.13 (down from CN¥0.25 in 3Q 2022). Revenue: CN¥535.1m (down 2.5% from 3Q 2022). Net income: CN¥72.0m (down 52% from 3Q 2022). Profit margin: 14% (down from 27% in 3Q 2022). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 7% per year.
お知らせ • Aug 18Cathay Biotech Inc. (SHSE:688065) announces an Equity Buyback for CNY 100 million worth of its shares.Cathay Biotech Inc. announces a share repurchase program. Under the program, the company will repurchase up to CNY 100 million worth of its shares. The program will be valid for a period of 12 months.
Price Target Changed • Aug 12Price target increased by 8.3% to CN¥67.18Up from CN¥62.00, the current price target is an average from 2 analysts. New target price is 9.6% above last closing price of CN¥61.30. Stock is down 23% over the past year. The company is forecast to post earnings per share of CN¥0.94 for next year compared to CN¥0.95 last year.
Reported Earnings • Aug 08Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.28 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.30 (up from CN¥0.28 in 2Q 2022). Revenue: CN¥525.0m (down 16% from 2Q 2022). Net income: CN¥184.4m (up 14% from 2Q 2022). Profit margin: 35% (up from 26% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.
お知らせ • Jun 28Cathay Biotech Inc. to Report First Half, 2023 Results on Aug 16, 2023Cathay Biotech Inc. announced that they will report first half, 2023 results on Aug 16, 2023
お知らせ • Jun 27Cathay Biotech Inc. announced that it expects to receive CNY 6.6 billion in funding from China Merchants Group LimitedCathay Biotech Inc. announced a private placement of common shares for gross proceeds up to CNY 6,600 million on June 25, 2023. The transaction will include participation from new investor China Merchants Group Limited. The transaction is subject to the approval of shareholders of the company.
Reported Earnings • Apr 26Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: CN¥0.95 (down from CN¥1.04 in FY 2021). Revenue: CN¥2.44b (up 11% from FY 2021). Net income: CN¥553.3m (down 9.0% from FY 2021). Profit margin: 23% (down from 28% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 23%. Earnings per share (EPS) also missed analyst estimates by 23%.
Reported Earnings • Mar 01Full year 2022 earnings released: EPS: CN¥0.95 (vs CN¥1.04 in FY 2021)Full year 2022 results: EPS: CN¥0.95 (down from CN¥1.04 in FY 2021). Revenue: CN¥2.44b (up 11% from FY 2021). Net income: CN¥552.4m (down 9.1% from FY 2021). Profit margin: 23% (down from 28% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 42% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Chemicals industry in China.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Nov 08Cathay Biotech Inc. announced that it has received $28 million in funding from Eight Roads Ventures, Sequoia China Investment Management LLP, Source Code Capital, Bits x BitesCathay Biotech Inc. announced that it has received $28,000,000 in a round of funding co-led by Eight Roads Ventures, Sequoia China Investment Management LLP on November 7, 2022. The transaction included participation from returning investors Source Code Capital, Bits x Bites.
Reported Earnings • Oct 28Third quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.29 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.25 (down from CN¥0.29 in 3Q 2021). Revenue: CN¥548.9m (down 11% from 3Q 2021). Net income: CN¥149.7m (down 8.5% from 3Q 2021). Profit margin: 27% (in line with 3Q 2021). Revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China.
Price Target Changed • Aug 15Price target increased to CN¥91.82Up from CN¥78.69, the current price target is provided by 1 analyst. New target price is 15% above last closing price of CN¥79.70. Stock is down 15% over the past year. The company is forecast to post earnings per share of CN¥1.31 for next year compared to CN¥1.04 last year.
Valuation Update With 7 Day Price Move • Jun 06Investor sentiment improved over the past weekAfter last week's 23% share price gain to CN¥106, the stock trades at a forward P/E ratio of 58x. Average forward P/E is 17x in the Chemicals industry in China. Total returns to shareholders of 11% over the past year.
Valuation Update With 7 Day Price Move • May 03Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥91.69, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 14x in the Chemicals industry in China. Total returns to shareholders of 16% over the past year.
Reported Earnings • Apr 27First quarter 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.34 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.42 (up from CN¥0.34 in 1Q 2021). Revenue: CN¥661.3m (up 36% from 1Q 2021). Net income: CN¥174.5m (up 24% from 1Q 2021). Profit margin: 26% (down from 29% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 20%, compared to a 43% growth forecast for the industry in China.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. No highly experienced directors. 3 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Apr 08Full year 2021 earnings released: EPS: CN¥1.46 (vs CN¥1.18 in FY 2020)Full year 2021 results: EPS: CN¥1.46 (up from CN¥1.18 in FY 2020). Revenue: CN¥2.20b (up 47% from FY 2020). Net income: CN¥607.9m (up 33% from FY 2020). Profit margin: 28% (down from 31% in FY 2020). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 24%, compared to a 50% growth forecast for the industry in China.
Valuation Update With 7 Day Price Move • Mar 08Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to CN¥115, the stock trades at a trailing P/E ratio of 79.6x. Average trailing P/E is 32x in the Chemicals industry in China. Total returns to shareholders of 43% over the past year.
Reported Earnings • Feb 28Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: EPS: CN¥1.45 (up from CN¥1.18 in FY 2020). Revenue: CN¥2.20b (up 47% from FY 2020). Net income: CN¥603.6m (up 32% from FY 2020). Profit margin: 28% (down from 31% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 24%. Earnings per share (EPS) exceeded analyst estimates by 1.7%.
Reported Earnings • Oct 31Third quarter 2021 earnings released: EPS CN¥0.40 (vs CN¥0.30 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: CN¥618.5m (up 72% from 3Q 2020). Net income: CN¥163.6m (up 42% from 3Q 2020). Profit margin: 26% (down from 32% in 3Q 2020). The decrease in margin was driven by higher expenses.
Reported Earnings • Aug 19Second quarter 2021 earnings released: EPS CN¥0.44 (vs CN¥0.23 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥527.2m (up 36% from 2Q 2020). Net income: CN¥185.1m (up 110% from 2Q 2020). Profit margin: 35% (up from 23% in 2Q 2020). The increase in margin was driven by higher revenue.
Reported Earnings • Apr 27First quarter 2021 earnings released: EPS CN¥0.34 (vs CN¥0.32 in 1Q 2020)The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: CN¥487.0m (up 20% from 1Q 2020). Net income: CN¥141.3m (up 19% from 1Q 2020). Profit margin: 29% (in line with 1Q 2020).
Reported Earnings • Apr 01Full year 2020 earnings released: EPS CN¥1.18 (vs CN¥1.32 in FY 2019)The company reported a soft full year result with weaker earnings and revenues, although profit margins were improved. Full year 2020 results: Revenue: CN¥1.50b (down 22% from FY 2019). Net income: CN¥457.7m (down 4.4% from FY 2019). Profit margin: 31% (up from 25% in FY 2019). The increase in margin was driven by lower expenses.
お知らせ • Mar 05Cathay Biotech Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021Cathay Biotech Inc. announced that they will report fiscal year 2020 results on Mar 30, 2021
Valuation Update With 7 Day Price Move • Feb 22Investor sentiment improved over the past weekAfter last week's 16% share price gain to CN¥89.29, the stock is trading at a trailing P/E ratio of 78.6x, up from the previous P/E ratio of 67.7x. This compares to an average P/E of 37x in the Chemicals industry in China.
Is New 90 Day High Low • Jan 27New 90-day low: CN¥82.67The company is down 10.0% from its price of CN¥92.00 on 29 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 21% over the same period.
Is New 90 Day High Low • Dec 23New 90-day low: CN¥88.56The company is down 11% from its price of CN¥99.97 on 24 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 6.0% over the same period.